Transcriptional regulation of macrophage arginase 1 expression and its role in atherosclerosis

Trends in Cardiovascular Medicine

Volumn 23, Issue 5, 2013, Pages 143-152

  Pourcet, Benoit ^a   Pineda Torra, Inés ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGININE; CCAAT ENHANCER BINDING PROTEIN BETA; CELL NUCLEUS RECEPTOR; INTERLEUKIN 4; KRUPPEL LIKE FACTOR 4; LIGAND; LIVER X RECEPTOR ALPHA; NITRIC OXIDE; NUCLEAR RECEPTOR NUR77; ORNITHINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT6 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PU 1; UREA; VITAMIN D RECEPTOR;

ATHEROSCLEROSIS; CELL POLARITY; ENZYME REGULATION; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE REPAIR; WOUND HEALING;

ANIMALS; ARGINASE; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERLEUKIN-4; MACROPHAGES; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TRANSCRIPTION, GENETIC;

EID: 84878825354     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.10.003     Document Type: Review

References (52)

1. Adamson S., Leitinger N. Phenotypic modulation of macrophages in response to plaque lipids. Current Opinion in Lipidology 2011, 22:335-342.
2. Butcher M.J., Galkina E.V. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Frontiers in Physiology 2012, 3:44.
3. Calkin A.C., Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:1513-1518.
4. Chinetti-Gbaguidi G., Baron M., Bouhlel M.A., Vanhoutte J., Copin C., Sebti Y., et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circulation Research 2011, 108:985-995.
5. Contursi C., Wang I.M., Gabriele L., Gadina M., O'Shea J., Morse H.C., et al. IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:91-96.
6. Dumont J., Zureik M., Cottel D., Montaye M., Ducimetiere P., Amouyel P., et al. Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. Journal of Medical Genetics 2007, 44:526-531.
7. Ehrchen J., Helming L., Varga G., Pasche B., Loser K., Gunzer M., et al. Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major. The FASEB Journal 2007, 21:3208-3218.
8. El Kasmi K.C., Qualls J.E., Pesce J.T., Smith A.M., Thompson R.W., Henao-Tamayo M., et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nature Immunology 2008, 9:1399-1406.
9. Erdely A., Kepka-Lenhart D., Clark M., Zeidler-Erdely P., Poljakovic M., Calhoun W.J., et al. Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages. American Journal of Physiology-Lung Cellular and Molecular Physiology 2006, 290:L534-539.
10. Feig J.E., Parathath S., Rong J.X., Mick S.L., Vengrenyuk Y., Grauer L., et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011, 123:989-998.
11. Feig J.E., Rong J.X., Shamir R., Sanson M., Vengrenyuk Y., Liu J., et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7166-7171.
12. Feig J.E., Pineda-Torra I., Sanson M., Bradley M.N., Vengrenyuk Y., Bogunovic D., et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. Journal of Clinical Investigation 2010, 120:4415-4424.
13. Gallardo-Soler A., Gomez-Nieto C., Campo M.L., Marathe C., Tontonoz P., Castrillo A., et al. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Molecular Endocrinology 2008, 22:1394-1402.
14. Gibbings S., Elkins N.D., Fitzgerald H., Tiao J., Weyman M.E., Shibao G., et al. Xanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}. Journal of Biological Chemistry 2011, 286:961-975.
15. Gordon S. Alternative activation of macrophages. Nature Reviews Immunology 2003, 3:23-35.
16. Gray M.J., Poljakovic M., Kepka-Lenhart D., Morris S.M. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 2005, 353:98-106.
17. Hamers A.A., Vos M., Rassam F., Marinkovic G., Kurakula K., van Gorp P.J., et al. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. Circulation Research 2012, 110:428-438.
18. Hanna R.N., Shaked I., Hubbeling H.G., Punt J.A., Wu R., Herrley E., et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circulation Research 2012, 110:416-427.
19. Heinz S., Benner C., Spann N., Bertolino E., Lin Y.C., Laslo P., et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular Cell 2010, 38:576-589.
20. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378-382.
21. Ishii M., Wen H., Corsa C.A., Liu T., Coelho A.L., Allen RM., et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009, 114:3244-3254.
22. Kadl A., Meher A.K., Sharma P.R., Lee M.Y., Doran AC, Johnstone S.R., et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circulation Research 2010, 107:737-746.
23. Khallou-Laschet J., Varthaman A., Fornasa G., Compain C., Gaston A.T., Clement M., et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010, 5:e8852.
24. Kiss E., Popovic Z., Bedke J., Wang S., Bonrouhi M., Gretz N., et al. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRalpha. American Journal of Pathology 2011, 179:92-103.
25. Liao X., Sharma N., Kapadia F., Zhou G., Lu Y., Hong H., et al. Kruppel-like factor 4 regulates macrophage polarization. Journal of Clinical Investigation 2011, 121:2736-2749.
26. Lieu H.D., Withycombe S.K., Walker Q., Rong J.X., Walzem R.L., Wong J.S., et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation 2003, 107:1315-1321.
27. Marathe C., Bradley M.N., Hong C., Chao L., Wilpitz D., Salazar J., et al. Preserved glucose tolerance in high-fat-fed C57BL/6 mice transplanted with PPARgamma-/-, PPARdelta-/-, PPARgammadelta-/-, or LXRalphabeta-/- bone marrow. Journal of Lipid Research 2009, 50:214-224.
28. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
29. Morris S.M. Recent advances in arginine metabolism: roles and regulation of the arginases. British Journal of Pharmacology 2009, 157:922-930.
30. Munder M. Arginase: an emerging key player in the mammalian immune system. British Journal of Pharmacology 2009, 158:638-651.
31. Munder M., Mollinedo F., Calafat J., Canchado J., Gil-Lamaignere C., Fuentes J.M., et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 2005, 105:2549-2556.
32. Nagy L., Szanto A., Szatmari I., Szeles L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiological Reviews 2012, 92:739-789.
33. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
34. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metabolism 2008, 7:496-507.
35. Pauleau A.L., Rutschman R., Lang R., Pernis A., Watowich S.S., Murray P.J. Enhancer-mediated control of macrophage-specific arginase I expression. Journal of Immunology 2004, 172:7565-7573.
36. Pesce J.T., Ramalingam T.R., Mentink-Kane M.M., Wilson M.S., El Kasmi K.C., Smith A.M., et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. Plos Pathogens 2009, 5:e1000371.
37. Pires N.M., Pols T.W., de Vries M.R., van Tiel C.M., Bonta P.I., Vos M., et al. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 2007, 115:493-500.
38. Pourcet B., Feig J.E., Vengrenyuk Y., Hobbs A.J., Kepka-Lenhart D., Garabedian M.J., et al. LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circulation Research 2011, 109:492-501.
39. Pourcet B., Fruchart J.C., Staels B., Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opinion on Emerging Drugs 2006, 11:379-401.
40. Qualls JE, Neale G, Smith AM, Koo MS, DeFreitas AA, Zhang H et al.: 2010. Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Science Signalling 3: ra62.
41. Raes G., Brys L., Dahal B.K., Brandt J., Grooten J., Brombacher F., et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. Journal of Leukocyte Biology 2005, 77:321-327.
42. Ramagopalan S.V., Heger A., Berlanga A.J., Maugeri N.J., Lincoln M.R., Burrell A., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Research 2010, 20:1352-1360.
43. Reis E.D., Li J., Fayad Z.A., Rong J.X., Hansoty D., Aguinaldo J.G., et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. Journal of Vascular Surgery 2001, 34:541-547.
44. Sediri Y., Kallel A., Ben Ali S., Omar S., Mourali M.S., Elasmi M., et al. Association of rs2781666 G/T polymorphism of arginase I gene with myocardial infarction in Tunisian male population. Clinical Biochemistry 2010, 43:106-109.
45. Sharda D.R., Yu S., Ray M., Squadrito M.L., De Palma M., Wynn T.A., et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. Journal of Immunology 2011, 187:2181-2192.
46. Szanto A., Balint B.L., Nagy Z.S., Barta E., Dezso B., Pap A., et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity 2010, 33:699-712.
47. Teupser D., Burkhardt R., Wilfert W., Haffner I., Nebendahl K., Thiery J. Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:365-371.
48. Thomas A.C., Sala-Newby G.B., Ismail Y., Johnson J.L., Pasterkamp G., Newby A.C. Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:571-577.
49. Trogan E., Feig J.E., Dogan S., Rothblat G.H., Angeli V., Tacke F., et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:3781-3786.
50. Vidal M., Ramana C.V., Dusso A.S. Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Molecular and Cellular Biology 2002, 22:2777-2787.
51. Ye S., Xu H., Jin J., Yang M., Wang C., Yu Y., et al. The E3 Ubiquitin Ligase Neuregulin Receptor Degradation Protein 1 (Nrdp1) Promotes M2 Macrophage Polarization by Ubiquitinating and Activating Transcription Factor CCAAT/Enhancer-binding Protein beta (C/EBPbeta). Journal of Biological Chemistry 2012, 287:26740-26748.
52. You B., Jiang Y.Y., Chen S., Yan G., Sun J. The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IkappaBalpha expression. Circulation Research 2009, 104:742-749.